Trial to Test Effectiveness of Depression Intervention for Mistreated Older Adults

Sponsor
Weill Medical College of Cornell University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04258579
Collaborator
National Institute of Mental Health (NIMH) (NIH)
50
1
1
26
1.9

Study Details

Study Description

Brief Summary

The investigators developed EM/PROTECT, a behavioral intervention for depressed EM (elderly mistreatment) victims, to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services. PROTECT is built on a model which postulates that chronic stress promotes dysfunction of the cognitive control (CCN) and reward networks, impairing the victims' ability to flexibly respond to the environment and limits their reward activities. PROTECT therapists work with victims to develop action plans to reduce stress, and to increase rewarding experiences. EM/PROTECT has been designed in an iterative process with community EM providers of the New York City (NYC) Department for the Aging (DFTA) to use agencies' routine PHQ-9 depression screening and referral for service. In the current study, the investigators will compare the effectiveness of EM/PROTECT with EM enriched with staff training in linking EM victims to community mental health services (EM/MH). The investigators intend to enroll 50 subjects that will participate in the study for approximately 12 weeks.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: PROTECT with Technology Augmentation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The investigators will be comparing data collected from this project to previously collected data from the first phase of this project, in which PROTECT was delivered only in-person.The investigators will be comparing data collected from this project to previously collected data from the first phase of this project, in which PROTECT was delivered only in-person.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
EM/PROTECT-Hybrid: Improving Depression in Elder Mistreatment Victims
Actual Study Start Date :
Jul 15, 2020
Anticipated Primary Completion Date :
Sep 15, 2022
Anticipated Study Completion Date :
Sep 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Video PROTECT

Participants will receive PROTECT therapy once a week for 9 weeks.

Behavioral: PROTECT with Technology Augmentation
PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.

Outcome Measures

Primary Outcome Measures

  1. Change in clinically significant depressive symptoms as measured by the MADRS [Baseline, 6 weeks, 9 weeks, 12 weeks]

    In all conditions, the change in clinically significant depressive symptoms as measured on the Montgomery Asberg Depression Rating Scale (MADRS). Scores are categorized as following: 0 to 6 - Normal /symptom absent. 7 to 19 - Mild depression. 20 to 34 - Moderate depression. >34 - Severe depression.

  2. Change in assessment of Quality of Life, as measured by the WHO-QOL [Baseline, 6 weeks, 9 weeks, 12 weeks]

    In all conditions, changes in assessment of quality of life measured by the World Health Organization Quality of Life (WHO-QOL) scale. Scores across 4 domains (Physical Health, Psychological, Social Relationships, and Environment) range from 0-100, with higher scores indicating a higher quality of life.

  3. Change in assessment of stress, as measured by the PSS [Baseline, 6 weeks]

    In all conditions, changes in assessment of stress measured by the Perceived Stress Scale (PSS) scale. Scores range from 0-40. Scores ranging from 0-13 are considered low stress, scores ranging from 14-26 are considered moderate stress, and scores ranging from 27-40 are considered high perceived stress.

Secondary Outcome Measures

  1. Change in assessment of exposure to meaningful activities, as measured by the BADS [Baseline, 6 weeks]

    In all conditions, changes in assessment of meaningful activities measured by the Behavioral Activation for Depression Scale (BADS). Scores are divided across 4 domains: Activation subscale scores range from 0-42, Avoidance/Rumination subscale scores range from 0-48, Work/School Impairment subscale scores range from 0-30, Social Impairment subscale scores range from 0-30. For all subscales, high scores are consistent with the subscale title (e.g., high scores on Activation subscale = more activation).

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 55 years of age or older

  • Capacity to consent (per Elder Mistreatment staff)

  • Significant depression (per Elder Mistreatment staff) as indicated by a score of 10 or above on the Patient Health Questionnaire-9 (PHQ-9), a widely used screening tool routinely administered in Elder Mistreatment (EM) agency settings (the PHQ-9 has a sensitivity of 88% and a specificity of 88% for major depression)

  • Need for EM services

Exclusion Criteria:
  • Active suicidal ideation (Montgomery Asberg Depression Rating Scale item 10>4)

  • Inability to speak English or Spanish

  • Axis 1 Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnoses other than unipolar depression or generalized anxiety disorder (by Structured Clinical Interview for DSM-5)

  • Severe or life-threatening medical illness

  • EM emergency and or referral out of EM agency (per EM staff)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Weill Cornell Medicine New York New York United States 10065

Sponsors and Collaborators

  • Weill Medical College of Cornell University
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Jo Anne Sirey, Ph.D., Weill Medical College of Cornell University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT04258579
Other Study ID Numbers:
  • 19-09020854
  • P50MH113838-03
First Posted:
Feb 6, 2020
Last Update Posted:
Jul 29, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Weill Medical College of Cornell University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2022